Tailoring glucocorticoids in patients with severe COVID-19: a narrative review.

ABSTRACT:

Objective

To discuss the pathogenesis of severe coronavirus disease 2019 (COVID-19) infection and the pharmacological effects of glucocorticoids (GCs) toward this infection. To review randomized controlled trials (RCTs) using GCs to treat patients with severe COVID-19, and investigate whether GC timing, dosage, or duration affect clinical outcomes. Finally. to discuss the use of biological markers, respiratory parameters, and radiological evidence to select patients for improved GC therapeutic precision.

Background

COVID-19 has become an unprecedented global challenge. As GCs have been used as key immunomodulators to treat inflammation-related diseases, they may play key roles in limiting disease progression by modulating immune responses, cytokine production, and endothelia

SUBMITTER: Luo MH 

PROVIDER: S-EPMC8421952 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature